2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
246
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Myelodysplastic Syndromes
144
Leukemia, Lymphocytic, Chronic, B-Cell
140
Leukemia
128
Multiple Myeloma
118
Lymphoma
116
Lymphoma, Non-Hodgkin
112
Recurrence
80
Hematologic Neoplasms
77
Melanoma
68
Hodgkin Disease
68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Lymphoma, B-Cell
61
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Burkitt Lymphoma
41
Ovarian Neoplasms
40
Neoplasms
39
Myeloproliferative Disorders
39
Neoplasm Metastasis
34
Lymphoma, B-Cell, Marginal Zone
30
Graft vs Host Disease
29
Neoplasms, Plasma Cell
28
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
27
Leukemia, Biphenotypic, Acute
25
Primary Myelofibrosis
24
Anemia, Refractory, with Excess of Blasts
23
Interventions
Immunotherapy, Adoptive
2
Bevacizumab
2
tislelizumab
1
fludarabine
1
codrituzumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Simpson-Golabi-Behmel syndrome
×
fludarabine
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled